However, at the same time, the controversy regarding the side effects of fracture risk and prostate cancer risk caused by PPARγ agonists has persisted in the past 10 years, which has also led to apparent restrictions on the clinical application of PPARγ activators for neurovascular protection in patients with diabetes. This evidence concerns the gene PPARG and prostate cancer.